IN183947B - - Google Patents

Info

Publication number
IN183947B
IN183947B IN1260DE1995A IN183947B IN 183947 B IN183947 B IN 183947B IN 1260DE1995 A IN1260DE1995 A IN 1260DE1995A IN 183947 B IN183947 B IN 183947B
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Jean Rene Autheline
Jacques Doveze
Elite Fouque
Bernadette Mandard
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9465183&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN183947(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of IN183947B publication Critical patent/IN183947B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Epoxy Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
IN1260DE1995 1994-07-08 1995-07-06 IN183947B (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9408479A FR2722191B1 (fr) 1994-07-08 1994-07-08 Procede de preparation du trihydrate du (2r,3s)-3-tertbutoxycarbonylamino-2-hydroxy-3-phenylpropionate de 4-acetoxy2alpha-benzoyloxy-5beta,20epoxy-1,7beta,10beta trihydroxy-9-oxo-tax-11-en-13alpha-yle

Publications (1)

Publication Number Publication Date
IN183947B true IN183947B (enExample) 2000-05-20

Family

ID=9465183

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1260DE1995 IN183947B (enExample) 1994-07-08 1995-07-06

Country Status (38)

Country Link
US (1) US6022985A (enExample)
EP (1) EP0770070B1 (enExample)
JP (1) JP3753155B2 (enExample)
KR (1) KR100391753B1 (enExample)
CN (1) CN1067996C (enExample)
AT (1) ATE171702T1 (enExample)
AU (1) AU706519B2 (enExample)
BR (1) BR9508789A (enExample)
CA (1) CA2193531C (enExample)
CO (1) CO4410189A1 (enExample)
CZ (1) CZ284695B6 (enExample)
DE (1) DE69505128T2 (enExample)
DK (1) DK0770070T3 (enExample)
DZ (1) DZ1905A1 (enExample)
ES (1) ES2121404T3 (enExample)
FI (1) FI119246B (enExample)
FR (1) FR2722191B1 (enExample)
GR (1) GR3027558T3 (enExample)
HU (1) HU220634B1 (enExample)
IL (1) IL114274A (enExample)
IN (1) IN183947B (enExample)
IS (1) IS2032B (enExample)
MA (1) MA23606A1 (enExample)
MX (1) MX9700173A (enExample)
MY (1) MY118481A (enExample)
NO (1) NO314500B1 (enExample)
NZ (1) NZ289455A (enExample)
PE (1) PE8697A1 (enExample)
PL (1) PL179876B1 (enExample)
RU (1) RU2126397C1 (enExample)
SI (1) SI0770070T1 (enExample)
SK (1) SK280520B6 (enExample)
TN (1) TNSN95071A1 (enExample)
TW (1) TW419473B (enExample)
UA (1) UA51624C2 (enExample)
UY (1) UY23991A1 (enExample)
WO (1) WO1996001815A1 (enExample)
ZA (1) ZA955646B (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0002922A3 (en) 1997-04-28 2003-03-28 Aventis Pharma Sa Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors
SE510650C2 (sv) * 1997-05-30 1999-06-14 Astra Ab Ny förening
FR2794771B1 (fr) 1999-06-11 2001-08-10 Aventis Pharma Sa Adenovirus recombinants codant pour le transporteur specifique de l'iode (nis)
US6853921B2 (en) 1999-07-20 2005-02-08 Halliburton Energy Services, Inc. System and method for real time reservoir management
US6266619B1 (en) * 1999-07-20 2001-07-24 Halliburton Energy Services, Inc. System and method for real time reservoir management
GB9920548D0 (en) * 1999-08-31 1999-11-03 Rhone Poulenc Rorer Sa Treatment of hepatocellular carcinoma
US6891050B2 (en) * 2001-08-10 2005-05-10 Dabur India Limited Process for the preparation of taxanes such as paclitaxel, docetaxel and structurally similar analogs
US6881852B2 (en) * 2002-02-05 2005-04-19 Dabur India Limited Process of purification of paclitaxel and docetaxel
US7247738B2 (en) * 2002-05-07 2007-07-24 Dabur India Limited Method of preparation of anticancer taxanes using 3-[(substituted-2-trialkylsilyl) ethoxycarbonyl]-5-oxazolidine carboxylic acids
US6900342B2 (en) * 2002-05-10 2005-05-31 Dabur India Limited Anticancer taxanes such as paclitaxel, docetaxel and their structural analogs, and a method for the preparation thereof
US6838569B2 (en) * 2002-12-16 2005-01-04 Dabur India Limited Process for preparation of paclitaxel trihydrate and docetaxel trihydrate
US7584165B2 (en) * 2003-01-30 2009-09-01 Landmark Graphics Corporation Support apparatus, method and system for real time operations and maintenance
US8703982B2 (en) * 2003-03-17 2014-04-22 Phyton Holdings Llc Purification of taxanes
CN1268619C (zh) * 2003-05-08 2006-08-09 上海迪赛诺化学制药有限公司 多烯紫杉醇三水化合物的制备方法
FR2859996B1 (fr) * 2003-09-19 2006-02-03 Aventis Pharma Sa Solvat acetonique du dimethoxy docetaxel et son procede de preparation
US7838551B2 (en) 2003-12-12 2010-11-23 Quiral Quimica do Basil S.A. Process for the preparation of concentrated, sterile injectable solutions containing docetaxel
US7142986B2 (en) * 2005-02-01 2006-11-28 Smith International, Inc. System for optimizing drilling in real time
CN100420681C (zh) * 2005-04-29 2008-09-24 上海奥锐特国际贸易有限公司 多烯紫杉醇三水物的制备方法
BRPI0615292A8 (pt) * 2005-08-31 2018-03-06 Abraxis Bioscience Llc composições e métodos para preparação de fármacos de má solubilidade em água com estabilidade aumentada
SI1931321T1 (sl) * 2005-08-31 2019-07-31 Abraxis Bioscience, Llc Sestave, ki zajemajo slabo vodotopne farmacevtske učinkovine in antimikrobna sredstva
TW200730518A (en) * 2005-10-12 2007-08-16 Sicor Inc Crystalline forms of docetaxel and processes for their preparation
KR100995390B1 (ko) 2006-01-02 2010-11-19 주식회사 삼양제넥스 무정형, 무수결정형 또는 수화 결정형 도세탁셀의 제조방법
US8280635B2 (en) * 2006-01-20 2012-10-02 Landmark Graphics Corporation Dynamic production system management
JP2009533330A (ja) * 2006-03-21 2009-09-17 ドクター レディズ ラボラトリーズ リミテッド ドセタキセルの多形体およびプロセス
WO2008051465A2 (en) * 2006-10-20 2008-05-02 Scinopharm Singapore Pte, Ltd. Process for making crystalline anhydrous docetaxel
KR100868116B1 (ko) * 2007-04-09 2008-11-10 한미약품 주식회사 도세탁셀·모노프로필렌글라이콜 내포화합물 및 이의제조방법
KR100878455B1 (ko) 2007-04-10 2009-01-13 한미약품 주식회사 안정한 무수결정형 도세탁셀 및 이의 제조방법
EP2173732A4 (en) * 2007-07-04 2011-09-07 Reddys Lab Ltd Dr PROCESSES FOR THE PREPARATION OF DOCETAXEL AND POLYMORPHIC
EP2080763A1 (en) * 2008-01-18 2009-07-22 INDENA S.p.A. Crystalline form I of ortataxel
DK2080764T3 (da) 2008-01-18 2012-09-24 Indena Spa Faste former af ortataxel
PL388144A1 (pl) 2009-05-29 2010-12-06 Przedsiębiorstwo Produkcyjno-Wdrożeniowe Ifotam Spółka Z Ograniczoną Odpowiedzialnością Solwaty (2R,3S)-3-tert-butoksykarbonylamino-2-hydroksy-3-fenylopropionianu 4-acetoksy-2α-benzoiloksy -5β,20-epoksy-1,7β,10β-trihydroksy-9-okso-taks-11-en-13α-ylu, sposób ich otrzymywania i zastosowanie
ES2621613T3 (es) 2009-11-04 2017-07-04 Emcure Pharmaceuticals Limited Un proceso mejorado para la preparación de derivados de taxano
EP2566474B1 (en) 2010-05-03 2017-11-15 Teikoku Pharma USA, Inc. Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
WO2012160568A1 (en) * 2011-05-23 2012-11-29 Shilpa Medicare Limited Process for preparing docetaxel trihydrate polymorph
PL2753355T3 (pl) 2011-09-08 2019-04-30 Benevir Biopharm Inc Onkolityczny wirus opryszczki pospolitej i jego zastosowania lecznicze
US9745631B2 (en) 2011-12-20 2017-08-29 Dana-Farber Cancer Institute, Inc. Methods for diagnosing and treating oncogenic kras-associated cancer
CN108686203A (zh) 2012-04-04 2018-10-23 哈洛齐梅公司 使用抗透明质酸剂和肿瘤靶向紫杉烷的组合疗法
CA2874521A1 (en) 2012-05-24 2013-11-28 Dana-Farber Cancer Institute, Inc. Targeting the glutamine to pyruvate pathway for treatment of oncogenic kras-associated cancer
US20150285802A1 (en) 2012-07-18 2015-10-08 Dana-Farber Cancer Institute, Inc. Methods for treating, preventing and predicting risk of developing breast cancer
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
EP2968406A4 (en) 2013-03-14 2016-10-26 Icahn School Med Mount Sinai WITH AUTOLOGOUS TUMORLYSAT-LOADED DENDRITIC CELL VACCINE FOR THE TREATMENT OF LIVER CANCER
US10130590B2 (en) 2013-10-01 2018-11-20 Dana-Farber Cancer Institute, Inc. Methods of treating cancer with atovaquone-related compounds
WO2015149006A2 (en) 2014-03-27 2015-10-01 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating ncoa4-mediated autophagic targeting of ferritin
MA39818A (fr) 2014-03-30 2017-02-08 Benevir Biopharm Inc Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques
WO2016205429A1 (en) 2015-06-15 2016-12-22 New York University Method of treatment using oncolytic viruses
WO2019222435A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US5229526A (en) * 1991-09-23 1993-07-20 Florida State University Metal alkoxides

Also Published As

Publication number Publication date
JPH10502627A (ja) 1998-03-10
RU2126397C1 (ru) 1999-02-20
KR100391753B1 (ko) 2004-02-11
CZ284695B6 (cs) 1999-02-17
MA23606A1 (fr) 1996-04-01
NO314500B1 (no) 2003-03-31
CO4410189A1 (es) 1997-01-09
SK697A3 (en) 1997-06-04
CZ3597A3 (en) 1997-04-16
TW419473B (en) 2001-01-21
DE69505128T2 (de) 1999-04-01
AU706519B2 (en) 1999-06-17
CN1151741A (zh) 1997-06-11
UA51624C2 (uk) 2002-12-16
CN1067996C (zh) 2001-07-04
EP0770070B1 (fr) 1998-09-30
FI970069L (fi) 1997-01-07
US6022985A (en) 2000-02-08
AU2930595A (en) 1996-02-09
WO1996001815A1 (fr) 1996-01-25
NO970007D0 (no) 1997-01-02
FR2722191A1 (fr) 1996-01-12
PL318195A1 (en) 1997-05-26
PL179876B1 (pl) 2000-11-30
DZ1905A1 (fr) 2002-02-17
IS2032B (is) 2005-08-15
MX9700173A (es) 1997-04-30
JP3753155B2 (ja) 2006-03-08
ATE171702T1 (de) 1998-10-15
CA2193531A1 (fr) 1996-01-25
PE8697A1 (es) 1997-03-26
HUT76833A (en) 1997-11-28
IL114274A0 (en) 1995-10-31
TNSN95071A1 (fr) 1996-02-06
SI0770070T1 (en) 1998-12-31
FR2722191B1 (fr) 1996-08-23
DK0770070T3 (da) 1999-03-01
BR9508789A (pt) 1997-10-21
GR3027558T3 (en) 1998-11-30
MY118481A (en) 2004-11-30
SK280520B6 (sk) 2000-03-13
NO970007L (no) 1997-01-02
IL114274A (en) 1999-04-11
HU9700041D0 (en) 1997-02-28
HU220634B1 (hu) 2002-03-28
CA2193531C (fr) 2006-12-05
FI970069A0 (fi) 1997-01-07
FI119246B (fi) 2008-09-15
ES2121404T3 (es) 1998-11-16
ZA955646B (en) 1996-02-21
KR970704721A (ko) 1997-09-06
NZ289455A (en) 1997-12-19
UY23991A1 (es) 1995-09-20
EP0770070A1 (fr) 1997-05-02
DE69505128D1 (de) 1998-11-05
IS4411A (is) 1997-01-07

Similar Documents

Publication Publication Date Title
TW267985B (enExample)
TW277203B (enExample)
IN182236B (enExample)
IN183947B (enExample)
EP0669187A3 (enExample)
EP0671407A3 (enExample)
TW265487B (enExample)
TW258816B (enExample)
IN191422B (enExample)
FR2728214B1 (enExample)
FR2724105B1 (enExample)
FR2728922B1 (enExample)
DK0685247T3 (enExample)
IN188101B (enExample)
TW280852B (enExample)
IN184268B (enExample)
ECSMU940034U (enExample)
ECSDI940182S (enExample)
ECSDI940185S (enExample)
IN189474B (enExample)
ECSDI940187S (enExample)
ECSDI940194S (enExample)
CU22453A3 (enExample)
ECSDI940203S (enExample)
IN183045B (enExample)